Fibroblast growth factor 23 is not associated with and does not induce arterial calcification

[1]  J. Navarro-González,et al.  Expression of FGF23/KLOTHO system in human vascular tissue. , 2013, International journal of cardiology.

[2]  C. Bondor,et al.  Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. , 2012, Clinical biochemistry.

[3]  M. Joffe,et al.  Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  B. Kestenbaum,et al.  Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). , 2012, Journal of the American College of Cardiology.

[5]  W. Richards,et al.  FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. , 2012, The Journal of clinical investigation.

[6]  Z. Massy,et al.  FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages , 2012, Osteoporosis International.

[7]  L. Hsiao,et al.  Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23 , 2012, Circulation.

[8]  M. Kuro-o,et al.  Fibroblast Growth Factor 23 Induces Left Ventricular Hypertrophy , 2012 .

[9]  L. Hofbauer,et al.  Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. , 2012, The Journal of clinical endocrinology and metabolism.

[10]  Josef Coresh,et al.  Chronic kidney disease , 2012, The Lancet.

[11]  M. Wolf,et al.  Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[12]  M. Budoff,et al.  Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[13]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[14]  M. Reilly,et al.  Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  A. Cheung,et al.  FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. , 2011, Journal of the American Society of Nephrology : JASN.

[16]  Harold I Feldman,et al.  CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[18]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[19]  G. Silvestrini,et al.  Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. , 2011, Journal of nephrology.

[20]  R. Kronmal,et al.  Thoracic aortic calcification and coronary heart disease events: the multi-ethnic study of atherosclerosis (MESA). , 2011, Atherosclerosis.

[21]  C. Giachelli,et al.  Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. , 2011, The American journal of pathology.

[22]  C. Zoccali,et al.  FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. , 2010, Kidney international.

[23]  M. Wolf,et al.  Forging forward with 10 burning questions on FGF23 in kidney disease. , 2010, Journal of the American Society of Nephrology : JASN.

[24]  R. Kronmal,et al.  Statistical Modeling of Agatston Score in Multi-Ethnic Study of Atherosclerosis (MESA) , 2010, PloS one.

[25]  L. Schurgers,et al.  The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.

[26]  T. Larsson.  The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  A. Go,et al.  Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[28]  K. K. Quan,et al.  Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. , 2009, Kidney international.

[29]  Thomas J. Wang,et al.  Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease , 2009, Circulation.

[30]  B. Kestenbaum,et al.  Association of serum phosphate with vascular and valvular calcification in moderate CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[31]  A. Kastrati,et al.  Relation between plasma fibroblast growth factor‐23, serum fetuin‐A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function , 2008, Clinical endocrinology.

[32]  J. Mourad.  Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. , 2008 .

[33]  B. Kestenbaum,et al.  Association of mild to moderate kidney dysfunction and coronary calcification. , 2008, Journal of the American Society of Nephrology : JASN.

[34]  M. Taal,et al.  Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[35]  Jason R. Stubbs,et al.  Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. , 2007, Journal of the American Society of Nephrology : JASN.

[36]  L. Quarles,et al.  How fibroblast growth factor 23 works. , 2007, Journal of the American Society of Nephrology : JASN.

[37]  P. Raggi,et al.  Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. , 2007, Kidney international.

[38]  M. Inaba,et al.  Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients , 2006, Osteoporosis International.

[39]  T. Yamashita,et al.  Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. , 2006, The Journal of clinical endocrinology and metabolism.

[40]  Xianwu Li,et al.  Role of the Sodium-Dependent Phosphate Cotransporter, Pit-1, in Vascular Smooth Muscle Cell Calcification , 2006, Circulation research.

[41]  K. Rosenblatt,et al.  Regulation of Fibroblast Growth Factor-23 Signaling by Klotho* , 2006, Journal of Biological Chemistry.

[42]  C. McIntyre,et al.  Vascular calcification and cardiovascular function in chronic kidney disease. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  I. Narita,et al.  Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. , 2005, Kidney international.

[44]  D. Miao,et al.  Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. , 2004, Endocrinology.

[45]  C. Ohlsson,et al.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. , 2004, Endocrinology.

[46]  T. Yoneya,et al.  FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. , 2004, Biochemical and biophysical research communications.

[47]  A. Go,et al.  The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. , 2003, Journal of the American Society of Nephrology : JASN.

[48]  K. Miyamoto,et al.  Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production* , 2003, The Journal of Biological Chemistry.

[49]  Sharon M Moe,et al.  Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. , 2002, Kidney international.

[50]  J. Blacher,et al.  Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal Disease , 2001, Hypertension.

[51]  M. McKee,et al.  Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.

[52]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[53]  Tadashi Kaname,et al.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.

[54]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[55]  M. Puato,et al.  Fibroblast growth factor 23 and the bone-vascular axis: lessons learned from animal studies. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[56]  M. Kuro-o,et al.  Klotho deficiency causes vascular calcification in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[57]  Jinghong Zhao,et al.  Decreased expression of klotho gene in uremic atherosclerosis in apolipoprotein E-deficient mice. , 2010, Biochemical and biophysical research communications.

[58]  D. Miao,et al.  Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. , 2009, American journal of physiology. Endocrinology and metabolism.

[59]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .

[60]  L. Hutchison,et al.  BONE METABOLISM AND DISEASE IN CHRONIC KIDNEY DISEASE , 2007 .

[61]  D. Ivanovski,et al.  Printed in U.SA , 1988 .

[62]  Y. Caliskan,et al.  Fibroblast Growth Factor-23 (fgf-23) Is Independently Correlated to Aortic Calcification in Haemodialysis Patients Department of Endocrinology and Association of Fgf-23 with Aortic Calcification 2679 , 2022 .